An observational study in Pulmonary Hypertension, sponsored by University of Giessen. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-07.
Sponsored by University of Giessen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Hypertension, Pulmonary by University of Giessen — 5 open to participants now, 5 under way, none of them phase 3. Hypertension, Pulmonary · University of Giessen.
Among the 13 studies in Hypertension, Pulmonary by University of Giessen, this one is the 10th largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2023, is one of 11 observational ones, and was the 12th registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.
Browse Hypertension, Pulmonary studies →5 of the 13 studies in Hypertension, Pulmonary by University of Giessen are open now, in 1 country. Recruiting first, the newest first:
University of Giessen · Sites in Germany
Ages 18+ · Healthy volunteers
University of Giessen · Sites in Germany
Healthy volunteers
University of Giessen · Sites in Germany
University of Giessen · Sites in Germany
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 163 Hypertension, Pulmonary studies recruiting now, 98 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 38 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 1 started in 2023.
This study's planned enrollment of 100 is close to the median of 110 across 380 observational studies indexed under Hypertension, Pulmonary.
Median enrollment 57 across the 2 interventional studies, 500 across the 11 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Giessen is the lead sponsor of 95 studies on the registry; 22 are open to participants now.
1 of the studies in Hypertension, Pulmonary by University of Giessen that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06409624University of GiessenAssociation Between Biomarkers and Kidney Function Decline in Pulmonary Hypertension | 2027-10 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Hypertension, Pulmonary by University of Giessen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn about the acute (days) changes in right ventricular functions caused by initiation of pharmacological therapies in patients with precapillary pulmonary hypertension. The main question it aims to answer is:
Pulmonary hypertension (PH) arises as a result of a vascular pathology affecting the pulmonary vessels, leading to an increase in resistance within the pulmonary circulation. The ability of the right ventricle to adapt to the elevated pressures caused by increased afterload is crucial for the progression and symptoms of the disease. This adaptation of the right ventricle to its afterload is referred to as ventriculoarterial coupling or RV-PA coupling, described by the ratio of contractility to afterload. Invasive pressure-volume loops (PV loops) are the gold standard for assessing RV-PA coupling. The loss of RV-PA coupling is considered a crucial factor in the development of right heart failure, the leading cause of mortality in patients with pulmonary hypertension. Therefore, reliable assessment of right cardiac function is essential for physicians to make informed decisions regarding further invasive diagnostics or therapy adjustments. Approved medications for the treatment of pulmonary arterial hypertension primarily induce pulmonary vasodilation, leading to a reduction in right ventricular afterload. The effects on right ventricular contractility and function, as represented by RV-PA coupling, are currently poorly understood and may not be consistent. In this study, 100 patients with PH requiring an inpatient stay for right heart catheterization will be equipped with a mobile, wireless system for invasive measurement of right ventricular pressure - the CorLog system (emka MEDICAL, Aschaffenburg, Germany). By combining continuously recorded pressure profiles with 3D echocardiographic volumetry, we will be able to generate PV loops and assess RV-PA coupling at various time points. The continuous monitoring of right ventricular pressure profiles throughout the entire hospital stay will allow us to capture the effects of newly initiated or expanded pulmonary vascular therapy on RV-PA coupling not only immediately but over several days. Furthermore, the 3D echocardiographic datasets will be analyzed using specialized software (ReVISION®, Argus Cognitive, Inc, Lebanon, NH) to mechanistically quantify the right ventricular contraction pattern and capture the immediate impact of pulmonary vasoreactive therapy on it. Additionally, a data pool will be created to validate the calculation of ejection fraction and RV-PA coupling based solely on pressure signals.
The study population includes patients with pre-capillary pulmonary hypertension (Nice classification groups 1, 3, or 4) who are scheduled to undergo right heart catheterization for clinical reasons as part of invasive diagnostics for:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Afterload
Responce of afterload (calculated from PV loops \[Ea\]) afterload during hospitalization to the initiation or escalation of pulmonary vascular therapy
Time frame: 3-7days
Contractility
Response of contractility (calculated from PV loops \[Ees\]) during hospitalization to the initiation or escalation of pulmonary vascular therapy
Time frame: 3-7days
Coupling
Response of Coupling (calculated from PV loops \[Ees/Ea\]) during hospitalization to the initiation or escalation of pulmonary vascular therapy
Time frame: 3-7days
Validation of Echo/CorLog PV-Loops
Validation of Echo/Corlog-generated PV loops based on conductance catheter-generated PV loops
Time frame: On first day
Validation of pressure-only methods
Validation of methods for calculating ejection fraction and RV-PA coupling using ventricular pressure signals
Time frame: 3-7days
Contraction patterns
Analysis of volumetric datasets of the right ventricle using ReVISION software. Isolated quantification of right ventricular systolic shortening along the ventricular axes in 3-dimensional space.
Time frame: 3-7 days
Started Feb 2023 (actual). Primary completion is estimated for Feb 2025, 24 months after the start.
Of 142 non-industry observational studies under Hypertension, Pulmonary, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 167. This study's planned 24 months is below that.
Counting every sponsor, half of 167 studies reached it within 59 months; a quarter within 24 and three quarters within 107.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Giessen